Background: One of the leading causes of morbidity and mortality amongst type 2 diabetic (T2DM) patients is Cardiovascular disease (CVD). Patients with T2DM are at a higher risk of developing CVD than non-diabetic patients. Statin therapy has been proven to be effective for the primary prevention of CVD amongst T2DM patients. The objective of this study was to determine the extent of statin therapy use for primary prevention of CVD in T2DM patients at TTH. Methods: A retrospective review of prescription records of T2DM patients who attended the Diabetes Clinic between January 1 2019 to March 31 2019 was conducted. Patient-specific data, evidence of T2DM Diagnosis and prescribed statin therapy were retrieved. Data was collected using a pre-structured tool and analyzed with STATA 15.0. Results: A total of 171 patients were included in this study. Of these, only 49%(84) patients received a statin. Atorvastatin 20mg was prescribed for 76%(64) patients, followed by atorvastatin 10mg for 22%(19) patients. Atorvastatin 40mg and simvastatin 20mg was the least prescribed at 1%(1) patient each. A total of 76% of statin therapies were of moderate-intensity dose, 23% were of low-intensity dose and only 1% was of high-intensity dose. Conclusion: Despite the overwhelming evidence supporting the cardiovascular benefits of statins in T2DM patients, these therapeutic agents are under-prescribed for T2DM patients at TTH with atorvastatin being the most frequently prescribed statin therapy.